While the results in term infants are consistent with our belief that capillary rarefaction in essential hypertension is likely to be a primary vascular abnormality, the results in preterm infants may suggest that the intrauterine environment may exert some influences on the remodeling of the microcirculation which may delay the onset of capillary rarefaction in these infants.
Abstract-Low birth weight predicts adult essential hypertension and is linked to increased cardiovascular mortality in adult life. A reduction in capillary density (ie, rarefaction) is a hallmark of essential hypertension, and evidence suggests that rarefaction precedes the onset of the rise in blood pressure, because it is found in normotensive individuals at high risk of developing hypertension, suggesting that rarefaction is likely to be a primary structural abnormality. We hypothesized that low birth weight infants would have significant capillary rarefaction at birth. We studied 44 low birth weight infants born to normotensive mothers (33 were born preterm, birth weight: 1823Ϯ446 g; and 11 were born at term, birth weight: 2339Ϯ177 g) and compared them with 71 infants born at term with normal weight (birth weight: 3333Ϯ519 g). We used orthogonal polarized spectroscopy to measure basal (ie, functional) and maximal (ie, structural) skin capillary densities. Low birth weight infants, whether born preterm or at term, had significantly higher functional capillary density (mean difference of 10.5 capillaries per millimeter squared; 95% CI: 6.6 -14.4 capillaries per millimeter squared; PϽ0.0001) and higher structural capillary density (mean difference of 11.1 capillaries per millimeter squared; 95% CI: 7.6 -14.5 capillaries per millimeter squared; PϽ0.0001) when compared with normal weight term infants. We conclude that low birth weight infants born to normotensive mothers do not have capillary rarefaction at birth. These results contradict what might have been predicted from the concept of the intrauterine origins of adult disease and suggest that microcirculatory abnormalities observed in individuals of low birth weight occur in postnatal life rather than during their intrauterine existence. (Hypertension. 2011;58:847-851.)Key Words: capillary rarefaction Ⅲ microcirculation Ⅲ hypertension Ⅲ low birth weight M icrocirculatory abnormalities and impaired tissue perfusion have been implicated in the pathogenesis of essential hypertension, obesity, diabetes mellitus, and insulin resistance. 1 In essential hypertension in particular, a reduction in the spatial density of arterioles and capillaries (ie, rarefaction) appears to play a central role. 2 We have shown previously that much of the capillary rarefaction in essential hypertension is attributed to the structural (ie, anatomic) absence of capillaries. 3 We have also shown significant capillary rarefaction in patients with borderline intermittent essential hypertension and in normotensive offspring of hypertensive parents, suggesting a familial predisposition in which capillary rarefaction represents a primary vascular abnormality that antedates the onset of sustained elevation of blood pressure (BP). 4,5 There is now a strong body of evidence showing that low birth weight (LBW), that is, birth weight of Ͻ2.5 kg regardless of gestation or causation, 6 is associated with structural and functional vascular abnormalities, 7 the development of essential hypertension, 8...
Twin infants with low and NBWs tend to have higher functional and structural capillary densities compared to singleton infants. Further longitudinal studies of skin capillary density and of retinal vascular parameters commencing from birth to various stages in early childhood are essential to identify the dynamics and the exact timing, if any, of the remodeling of microcirculation in these individuals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.